- Phase 1 clinical trial evaluated multiple doses of LB-102 (N-methyl amisulpride) in 64 healthy adults ages 18-55 years
- LB-102 was safe and well-tolerated and displayed dose linear PK
- Phase 2 clinical study in schizophrenia patients planned for mid- 2021; retains Mizuho Securities as exclusive financial advisor
New York, NY (Sept 14th, 2020) – LB Pharmaceuticals Inc, (“LB”, or the “Company”), a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the results of a Phase 1 clinical study of LB-102 (NCT04187560), a novel derivative of amisulpride designed to treat schizophrenia.
Data from this study were presented at the 33rd annual meeting of the European College of Neuropsychopharmacology (ECNP), which is being held virtually. A copy of the Company’s poster can be viewed online at http://lbpharma.us/presentations/
This was a combined single ascending dose (SAD)/multiple ascending dose (MAD) study with safety as the primary endpoint and PK as a secondary endpoint. Sixty-four healthy volunteers were dosed orally with LB-102 at doses ranging from 10 mg to 200 mg. Top line results of this study include: